Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lantheus Holdings, Inc.LNTH · Entity 690 | Chief Medical Officer | July 08, 2019 | July 10, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lantheus Holdings, Inc.
Report date July 08, 2019 · Filed July 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,483 |
Ending reported balance
After 2019-07-08 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2019-07-08 · Exercise / conversion · Acquired 6,672 · Balance 75,155 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. Row 2 · 2019-07-08 · Exercise / conversion · Acquired 13,346 · Balance 88,501 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. Row 3 · 2019-07-08 · Exercise / conversion · Acquired 6,672 · Balance 95,173 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. Row 4 · 2019-07-08 · Exercise / conversion · Acquired 8,896 · Balance 104,069 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. Row 5 · 2019-07-08 · Sale · Disposed 28,002 · Balance 76,067 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.45, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc. ("LNTH"), any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Row 6 · 2019-07-08 · Sale · Disposed 7,584 · Balance 68,483 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.06 to $27.99, inclusive. The reporting person undertakes to provide to LNTH, any security holder of LNTH or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2023-03-04 | Direct | 0 |
Reported balance
After 2019-07-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-07-08 · Exercise / conversion · Disposed 6,672 · Balance 0 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2023-03-04 | Direct | 0 |
Reported balance
After 2019-07-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-07-08 · Exercise / conversion · Disposed 13,346 · Balance 0 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. F4: These options vested in four equal installments on March 4, 2014, 2015, 2016 and 2017. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2023-03-04 | Direct | 0 |
Reported balance
After 2019-07-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-07-08 · Exercise / conversion · Disposed 6,672 · Balance 0 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. F5: Options to purchase 13,345 shares of Common Stock were granted to the reporting person on March 4, 2013, which options were subject to vesting in up to four equal annual installments based upon the level of LNTH's satisfaction of certain performance criteria for each of fiscal years 2013, 2014, 2015 and 2016. A certain level of the performance criteria were satisfied for each of fiscal years 2013 and 2014, resulting in the partial vesting as to 6,672 shares of Common Stock. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.66 · Expires 2023-08-05 | Direct | 0 |
Reported balance
After 2019-07-08 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-07-08 · Exercise / conversion · Disposed 8,896 · Balance 0 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. F6: These options vested in four equal installments on August 5, 2014, 2015, 2016 and 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.45, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc. ("LNTH"), any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.06 to $27.99, inclusive. The reporting person undertakes to provide to LNTH, any security holder of LNTH or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
F4: These options vested in four equal installments on March 4, 2014, 2015, 2016 and 2017.
F5: Options to purchase 13,345 shares of Common Stock were granted to the reporting person on March 4, 2013, which options were subject to vesting in up to four equal annual installments based upon the level of LNTH's satisfaction of certain performance criteria for each of fiscal years 2013, 2014, 2015 and 2016. A certain level of the performance criteria were satisfied for each of fiscal years 2013 and 2014, resulting in the partial vesting as to 6,672 shares of Common Stock.
F6: These options vested in four equal installments on August 5, 2014, 2015, 2016 and 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2019 Filed Jul 10, 2019 20:05 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionStock Option (right to buy) · Derivative | 8,896 | $0.00 Strike: $18.66 | $0.00 |
DisclosureSEC source: 0000899243-19-019423 · doc4.xml · derivative · entry 10 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,896 shares Expires 2023-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. F6 · derivative.exercise_date: These options vested in four equal installments on August 5, 2014, 2015, 2016 and 2017. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 20:05 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionStock Option (right to buy) · Derivative | 6,672 | $0.00 Strike: $21.10 | $0.00 |
DisclosureSEC source: 0000899243-19-019423 · doc4.xml · derivative · entry 9 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,672 shares Expires 2023-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. F5 · derivative.exercise_date: Options to purchase 13,345 shares of Common Stock were granted to the reporting person on March 4, 2013, which options were subject to vesting in up to four equal annual installments based upon the level of LNTH's satisfaction of certain performance criteria for each of fiscal years 2013, 2014, 2015 and 2016. A certain level of the performance criteria were satisfied for each of fiscal years 2013 and 2014, resulting in the partial vesting as to 6,672 shares of Common Stock. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 20:05 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionStock Option (right to buy) · Derivative | 13,346 | $0.00 Strike: $21.10 | $0.00 |
DisclosureSEC source: 0000899243-19-019423 · doc4.xml · derivative · entry 8 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,346 shares Expires 2023-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. F4 · derivative.exercise_date: These options vested in four equal installments on March 4, 2014, 2015, 2016 and 2017. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 20:05 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionStock Option (right to buy) · Derivative | 6,672 | $0.00 Strike: $21.10 | $0.00 |
DisclosureSEC source: 0000899243-19-019423 · doc4.xml · derivative · entry 7 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,672 shares Expires 2023-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 20:05 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 7,584 | $27.60 | $209,318.40 |
DisclosureSEC source: 0000899243-19-019423 · doc4.xml · nonDerivative · entry 6 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,483 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.06 to $27.99, inclusive. The reporting person undertakes to provide to LNTH, any security holder of LNTH or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 20:05 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 28,002 | $28.33 | $793,296.66 |
DisclosureSEC source: 0000899243-19-019423 · doc4.xml · nonDerivative · entry 5 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,067 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.45, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc. ("LNTH"), any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 20:05 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionCommon Stock | 8,896 | $21.10 | $187,705.60 |
DisclosureSEC source: 0000899243-19-019423 · doc4.xml · nonDerivative · entry 4 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 20:05 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionCommon Stock | 6,672 | $21.10 | $140,779.20 |
DisclosureSEC source: 0000899243-19-019423 · doc4.xml · nonDerivative · entry 3 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 20:05 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionCommon Stock | 13,346 | $21.10 | $281,600.60 |
DisclosureSEC source: 0000899243-19-019423 · doc4.xml · nonDerivative · entry 2 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 20:05 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Exercise / conversionCommon Stock | 6,672 | $21.10 | $140,779.20 |
DisclosureSEC source: 0000899243-19-019423 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 7, 2019. Read SEC document |
| April 29, 2019 Filed May 1, 2019 20:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 11,250 | $24.85 | $279,616.50 |
DisclosureSEC source: 0000899243-19-011590 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,483 F1 · kind: Starting in 2019, the Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions under 10b5-1 plans. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2018, in part, to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.37 to $25.23, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 21:35 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 4,271 | $22.77 | $97,237.86 |
DisclosureSEC source: 0000899243-19-006916 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,733 F1 · kind: Starting in 2019, the Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions under 10b5-1 plans. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2018, in part, to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.57 to $23.02, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 21:15 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 3,111 | $23.10 | $71,870.32 |
DisclosureSEC source: 0000899243-19-005210 · doc4.xml · nonDerivative · entry 2 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,004 F1 · kind: Starting in 2019, the Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions under 10b5-1 plans. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2018, to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.56 to $23.62, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:15 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 13,426 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005210 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,115 Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 4,057 | $18.06 | $73,269.42 |
DisclosureSEC source: 0000899243-19-003034 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,689 F1 · kind: The transaction reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2018. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 21:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 3,060 | $16.56 | $50,676.66 |
DisclosureSEC source: 0000899243-19-002316 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,746 F1 · kind: Starting in 2019, the Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions under 10b5-1 plans. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2018, to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.31 to $16.82, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., ("LNTH") any security holder of LNTH or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 21:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 4,058 | $18.02 | $73,125.16 |
DisclosureSEC source: 0000899243-18-029950 · doc4.xml · nonDerivative · entry 4 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,806 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018. Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 21:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 800 | $18.00 | $14,400.00 |
DisclosureSEC source: 0000899243-18-029950 · doc4.xml · nonDerivative · entry 3 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,864 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 21:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 400 | $18.01 | $7,204.00 |
DisclosureSEC source: 0000899243-18-029950 · doc4.xml · nonDerivative · entry 2 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,664 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 21:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 1,797 | $18.00 | $32,346.00 |
DisclosureSEC source: 0000899243-18-029950 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,064 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 20:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Tax withholdingCommon Stock | 2,945 | $15.55 | $45,794.75 |
DisclosureSEC source: 0000899243-18-023847 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,861 F1 · kind: The transaction reported on this Form 4 represents the disposition of shares withheld by the Company to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 716 | $18.00 | $12,888.00 |
DisclosureSEC source: 0000899243-18-011289 · doc4.xml · nonDerivative · entry 2 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,806 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 3,794 | $18.05 | $68,481.70 |
DisclosureSEC source: 0000899243-18-011289 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,522 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018. Read SEC document |
| April 30, 2018 Filed May 1, 2018 21:14 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 600 | $18.00 | $10,800.00 |
DisclosureSEC source: 0000899243-18-011028 · doc4.xml · nonDerivative · entry 3 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,316 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018. Read SEC document |
| April 27, 2018 Filed May 1, 2018 21:14 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 1,300 | $18.03 | $23,439.00 |
DisclosureSEC source: 0000899243-18-011028 · doc4.xml · nonDerivative · entry 2 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,916 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018. Read SEC document |
| April 27, 2018 Filed May 1, 2018 21:14 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 6,901 | $18.00 | $124,218.00 |
DisclosureSEC source: 0000899243-18-011028 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,216 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2018. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 20:10 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 4,194 | $18.00 | $75,492.00 |
DisclosureSEC source: 0000899243-18-010879 · doc4.xml · nonDerivative · entry 2 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,117 F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 4, 2017. Read SEC document |
| April 26, 2018 Filed Apr 27, 2018 20:10 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Tax withholdingCommon Stock | 3,314 | $17.90 | $59,320.60 |
DisclosureSEC source: 0000899243-18-010879 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,311 F1 · kind: The transaction reported on this Form 4 represents the disposition of shares withheld by the Company to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:31 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 25,629 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-006641 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,625 Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 22:00 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Tax withholdingCommon Stock | 1,082 | $19.80 | $21,423.60 |
DisclosureSEC source: 0000899243-18-005640 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,996 F1 · kind: The transaction reported on this Form 4 represents the disposition of shares withheld by the Company to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 21:35 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | SaleCommon Stock | 18,000 | $16.69 | $300,475.80 |
DisclosureSEC source: 0000899243-17-021612 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,078 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 4, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $16.85, inclusive. The reporting person undertakes to provide to Lantheus Holdings, Inc., any security holder of Lantheus Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| September 01, 2017 Filed Sep 2, 2017 00:12 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Tax withholdingCommon Stock | 3,245 | $16.80 | $54,516.00 |
DisclosureSEC source: 0000899243-17-021384 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,078 F1 · kind: The transaction reported on this Form 4 represents the disposition of shares withheld by the Company to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4. Read SEC document |
| July 26, 2017 Filed Jul 28, 2017 20:05 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 18,672 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-019281 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,323 Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 20:02 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Tax withholdingCommon Stock | 3,651 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-011190 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,651 F1 · kind: The transaction reported on this Form 4 represents the disposition of shares withheld by the Company to satisfy withholding tax liabilities of the Reporting Person associated with the initial vesting of restricted stock previously granted and reported on a previously filed Form 4. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 21:05 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Tax withholdingCommon Stock | 2,687 | $8.85 | $23,779.95 |
DisclosureSEC source: 0000899243-17-002352 · doc4.xml · nonDerivative · entry 1 Orlandi Cesare · CIK 0001610664 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,302 F1 · kind: The transaction reported on this Form 4 represents the disposition of shares withheld by the Company to satisfy withholding tax liabilities of the Reporting Person associated with the initial vesting of restricted stock previously granted and reported on a previously filed Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.